

## **NEW YORK STATE MEDICAID PROGRAM – DISPENSE BRAND DRUGS WHEN LESS EXPENSIVE**

On April 26, 2010, New York Medicaid implemented a new cost containment initiative which promotes the use of certain multi-source brand name drugs when the cost of the brand name drug is less expensive than the generic equivalent.

**In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:**

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription**
- have a generic copayment;
- will be paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (neither the SMAC nor FUL will be applied);

### **IMPORTANT BILLING INFORMATION**

- Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and
- **Pharmacies can submit any valid NCPDP field (408-D8) value.**

**Effective February 10, 2012, Combivir will be added to the dispense brand when less expensive program.**

*Current list of Brand name drugs included in this program\* (Date Revised 2/10/2012):*

- **Adderall XR**
- **Arixtra**
- **Astelin**
- **Carbatrol**
- **Combivir**
- **Concerta**
- **Diastat**
- **Kadian**
- **Lipitor**
- **Lovenox**
- **Nasacort AQ**
- **Uroxatral**
- **Valtrex**
- **Zyprexa tablet**

\* List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs; again promoting the use of the most cost-effective product.